دورية أكاديمية
أعرض في EDS

Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes?

التفاصيل البيبلوغرافية
العنوان: Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes?
المؤلفون: Krasnikova V; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Pospelova M; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Fionik O; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Alekseeva T; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Samochernykh K; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Ivanova N; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Trofimov N; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Vavilova T; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Vasilieva E; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Makhanova A; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Tonyan S; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Nikolaeva A; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Kayumova E; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia., Shevtsov M; Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, Russia.; Department of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaninger Str. 22, 81675 Munich, Germany.; Laboratory of Biomedical Nanotechnologies, Institute of Cytology of the Russian Academy of Sciences (RAS), Tikhoretsky Ave., 4, 194064 Saint Petersburg, Russia.; Laboratory of Biomedical Cell Technologies, Far Eastern Federal University, 690091 Vladivostok, Russia.
المصدر: Pathophysiology : the official journal of the International Society for Pathophysiology [Pathophysiology] 2022 Sep 01; Vol. 29 (3), pp. 537-554. Date of Electronic Publication: 2022 Sep 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9433813 Publication Model: Electronic Cited Medium: Internet ISSN: 1873-149X (Electronic) Linking ISSN: 09284680 NLM ISO Abbreviation: Pathophysiology Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2020-: Basel : MDPI
Original Publication: Amsterdam ; New York : Elsevier, c1994-c2019.
مستخلص: Various complications from a breast cancer treatment, in the pathogenesis of which excessive tissue fibrosis plays a leading role, are a common pathology. In this study, the levels of TGF-β1, VEGFR-2, and TIMP-2 were determined by the immuno-enzyme serum analysis for patients during the long-term period after breast cancer treatment as potential markers of fibrosis. The single-center study enrolled 92 participants, which were divided into two age-matched groups: (1) 67 patients following breast cancer treatment, and (2) 25 healthy female volunteers. The intergroup analysis demonstrated that the patients after breast cancer treatment showed a decrease in the serum levels of TGF-β1 (U = 666, p < 0.001) and TIMP-2 (U = 637, p < 0.001) as compared to the group of healthy volunteers. The levels of VEGFR-2 in these groups were comparable (U = 1345, p = 0.082). It was also found that the type of treatment, the presence of lymphedema, shoulder joint contracture, and changes in lymphoscintigraphy did not affect the levels of TGF-β1, VEGFR-2, and TIMP-2 within the group of patients after breast cancer treatment. These results may indicate that these biomarkers do not play a leading role in the maintenance and progression of fibrosis in the long-term period after breast cancer treatment. The reduced levels of TGF-β1 and TIMP-2 may reflect endothelial dysfunction caused by the antitumor therapy.
References: Lymphat Res Biol. 2016 Sep;14(3):162-71. (PMID: 27599355)
J Cell Mol Med. 2020 Jul;24(14):7717-7729. (PMID: 32536032)
Rom J Morphol Embryol. 2018;59(2):455-467. (PMID: 30173249)
Biomolecules. 2021 Aug 19;11(8):. (PMID: 34439906)
Mutat Res Genet Toxicol Environ Mutagen. 2016 Oct;809:24-32. (PMID: 27692296)
J Neurobiol. 2006 Oct;66(12):1365-77. (PMID: 16967503)
Biochim Biophys Acta. 2010 Jan;1803(1):55-71. (PMID: 20080133)
Microvasc Res. 2006 Nov;72(3):161-71. (PMID: 16876204)
Cell. 2019 Mar 7;176(6):1248-1264. (PMID: 30849371)
Rev Bras Enferm. 2018 Nov-Dec;71(6):2916-2921. (PMID: 30517393)
Nat Rev Cancer. 2007 Mar;7(3):192-201. (PMID: 17318212)
Cancer Invest. 2007 Sep;25(6):373-7. (PMID: 17882646)
Ann Neurol. 2017 Jun;81(6):772-781. (PMID: 28486769)
Vox Sang. 2021 May;116(5):533-539. (PMID: 33107073)
Eur J Cancer. 2011 Jul;47(11):1669-75. (PMID: 21658938)
Eur J Pain. 2009 May;13(5):478-85. (PMID: 18635381)
Semin Cell Dev Biol. 2020 May;101:123-139. (PMID: 31879265)
J Cell Mol Med. 2021 Dec;25(24):11290-11299. (PMID: 34783198)
Connect Tissue Res. 2012;53(6):469-77. (PMID: 22512703)
Curr Probl Cancer. 2019 Dec;43(6):100470. (PMID: 30898366)
Adv Gerontol. 2018;31(2):223-230. (PMID: 30080329)
Lab Invest. 2010 Mar;90(3):374-82. (PMID: 20084057)
Am J Physiol Cell Physiol. 2010 Sep;299(3):C589-605. (PMID: 20519446)
Matrix Biol. 2015 May-Jul;44-46:247-54. (PMID: 25805621)
J Invest Dermatol. 2014 Mar;134(3):818-826. (PMID: 24042342)
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):43-46. (PMID: 30134384)
J Biochem. 2012 Oct;152(4):321-9. (PMID: 22923731)
Lymphology. 2013 Mar;46(1):1-11. (PMID: 23930436)
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):399-404. (PMID: 14699019)
Nature. 1992 Oct 22;359(6397):693-9. (PMID: 1436033)
Cell Mol Life Sci. 2019 Apr;76(7):1255-1273. (PMID: 30535789)
BMB Rep. 2018 Feb;51(2):73-78. (PMID: 29397867)
Clin Obstet Gynecol. 2016 Dec;59(4):651-672. (PMID: 27681694)
Br J Cancer. 2013 Jan 15;108(1):91-8. (PMID: 23321513)
Hum Pathol. 2009 Oct;40(10):1365-76. (PMID: 19695676)
Dose Response. 2018 Sep 24;16(3):1559325818799561. (PMID: 30263020)
Biochim Biophys Acta. 2010 Aug;1806(1):108-21. (PMID: 20462514)
PLoS One. 2014 Nov 17;9(11):e112624. (PMID: 25401336)
Brain Imaging Behav. 2015 Jun;9(2):275-84. (PMID: 24858488)
Cell Mol Life Sci. 2019 Feb;76(4):699-728. (PMID: 30377700)
Biomolecules. 2020 Mar 23;10(3):. (PMID: 32210029)
Am J Respir Crit Care Med. 2008 Jan 1;177(1):82-90. (PMID: 17916808)
Nature. 2020 Nov;587(7835):555-566. (PMID: 33239795)
Exp Ther Med. 2021 Sep;22(3):963. (PMID: 34335905)
Oncol Lett. 2020 Mar;19(3):2085-2096. (PMID: 32194706)
J Cell Physiol. 2012 Dec;227(12):3828-36. (PMID: 22495824)
Am Heart J. 2008 Jul;156(1):85-91. (PMID: 18585501)
J Clin Invest. 2014 Mar;124(3):915-21. (PMID: 24590276)
PLoS One. 2012;7(7):e41126. (PMID: 22911751)
Pathophysiology. 2022 Feb 16;29(1):52-65. (PMID: 35366289)
PLoS One. 2010 Jun 11;5(6):e11084. (PMID: 20552031)
Chem Biol Interact. 2018 Aug 25;292:76-83. (PMID: 30017632)
Radiat Res. 2011 Oct;176(4):415-24. (PMID: 21861763)
Nat Commun. 2015 Feb 04;6:6196. (PMID: 25648335)
Lymphat Res Biol. 2019 Jun;17(3):288-293. (PMID: 30358483)
CA Cancer J Clin. 2015 Jan-Feb;65(1):55-81. (PMID: 25410402)
J Inflamm (Lond). 2019 May 29;16:11. (PMID: 31160885)
Curr Breast Cancer Rep. 2021 Mar;13(1):1-18. (PMID: 34322193)
Transl Res. 2019 Jul;209:68-76. (PMID: 31022376)
Medicine (Baltimore). 2020 May;99(20):e19834. (PMID: 32443289)
Respirology. 2018 Jan;23(1):68-75. (PMID: 28834088)
Cells. 2020 Sep 09;9(9):. (PMID: 32917003)
Int J Mol Sci. 2017 Jan 17;18(1):. (PMID: 28106728)
J Immunol. 1993 May 15;150(10):4494-503. (PMID: 7683321)
Transl Oncol. 2019 Jan;12(1):162-169. (PMID: 30342294)
Clin Hemorheol Microcirc. 2013;54(4):371-9. (PMID: 23089880)
J Transl Med. 2021 May 1;19(1):186. (PMID: 33933107)
Acta Oncol. 2013 Feb;52(2):259-69. (PMID: 23215829)
Cell Tissue Res. 2016 Sep;365(3):591-605. (PMID: 27345301)
Cell. 1990 Nov 2;63(3):515-24. (PMID: 2171777)
Cell. 2003 Jul 25;114(2):171-80. (PMID: 12887919)
J Surg Oncol. 2020 Jan;121(1):37-47. (PMID: 31209893)
Int J Mol Sci. 2018 Apr 26;19(5):. (PMID: 29701666)
Cell Signal. 2007 Oct;19(10):2003-12. (PMID: 17658244)
Rev Assoc Med Bras (1992). 2008 Sep-Oct;54(5):467-70. (PMID: 18989570)
معلومات مُعتمدة: № 075-15-2020-901 Ministry of Science and Higher Education of the Russian Federation
فهرسة مساهمة: Keywords: TGF-β1; TIMP-2; VEGFR2; breast cancer; breast cancer survivors; breast cancer-related lymphedema; fibrosis molecules; post-mastectomy pain syndrome; post-radiation fibrosis
تواريخ الأحداث: Date Created: 20220922 Latest Revision: 20230308
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9500649
DOI: 10.3390/pathophysiology29030042
PMID: 36136069
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-149X
DOI:10.3390/pathophysiology29030042